关键词: 阿比特龙, 内分泌治疗, 转移去势抵抗前列腺癌, 老年

Abstract: ［Abstract］ Objective To observe the clinical efficacy and safety of abiraterone combined with prednisone for treating elderly metastatic castration?resistant prostate cancer （mCRPC）. Methods Thirty?six elderly patients with mCRPC in our hospital from January 2017 to January 2019 were enrolled in the study. These patients received abiraterone （1，000 mg once daily） plus prednisone （5 mg twice daily）. The PSA response rate and side effects of the drugs were recorded. Results The median follow?up time was 15.8 months. 23 patients had a PSA overall relief. According to the baseline， PSA baseline value can be divided into different levels： PSA ≤ 100 ng/mL， >100 ng/mL， the PSA response rates were 64.7%， 63.2%. The Gleason scores were divided into <8， =8， >8， with the PSA remission rate of 42.8%， 63.6%， 90.9%. The numbers of osseous metastasis in the mCRPC patients were divided into ≤10， >10， the response rates were 54.5%， 60%. There were 8 cases with PSA Flare in 23 cases of PSA relief， and 10 cases in total 36 patients. There were 7 cases with remission in 10 cases. IN the no PSA Flare phenomenon cases， 15 cases had PSA response. The main adverse effect （AE） were abnormal liver function， hypokalemia， edema and hypertension. There was no AE leading to discontinuation of drug therapy. Conclusion The abiraterone plus prednisone treatment is an effective and safe option to elderly mCRPC patients. In addition to Gleason scores， patients with different baseline values have not correlated therapeutic effect. The PSA Flare has a more positive response of the tumor to the drug.

Key words: endocrinotherapy, metastatic castration?resistant prostate cancer, elderly, abiraterone